Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Most solid tumors overexpress cyclooxygenase-2 (COX-2), a validated target for non-steroidal anti-inflammatory drugs (NSAIDs).
• COX-2 overexpression is linked to advanced disease stage and poorer prognosis in various solid malignancies.
• NSAIDs exhibit anti-cancer properties by inhibiting tumor proliferation, invasiveness, and angiogenesis, while also overcoming apoptosis resistance.

Purpose of the Study:

• To review the rationale for using NSAIDs, including selective COX-2 inhibitors, as anti-cancer drugs.
• To explore the potential of combining NSAIDs with conventional chemotherapy or novel targeted therapies.
• To discuss the modulation of key cancer-related pathways by NSAIDs.

Main Methods:

• Review of preclinical studies (cell lines, xenograft models) investigating NSAID anti-cancer effects.
• Analysis of studies examining NSAID mechanisms of action, including pathway modulation (Akt, NF-kappaB, tyrosine kinase, apoptosis).
• Evaluation of ongoing clinical trials assessing NSAIDs in cancer treatment.

Main Results:

• Preclinical studies demonstrate that NSAIDs modulate critical signaling pathways involved in cancer progression and survival.
• NSAIDs exhibit anti-proliferative, anti-invasive, and anti-angiogenic effects, and can induce apoptosis in tumor cells.
• Despite cardiovascular risks associated with selective COX-2 inhibitors, clinical trials continue to explore their therapeutic benefits in oncology.

Conclusions:

• NSAIDs, especially selective COX-2 inhibitors, represent a promising therapeutic strategy in oncology, often in combination regimens.
• Further clinical evaluation is necessary to balance the anti-tumor efficacy of NSAIDs against their potential side effects.
• The precise role of selective COX-2 inhibitors in cancer treatment will be defined by ongoing clinical trial data.